3:16 PM
Mar 13, 2018
 |  BC Extra  |  Financial News

Escalier raises $19M series B

Escalier Biosciences B.V. (Nijmegen, Netherlands) raised $19 million in a series B round led by Forbion. Existing investors New Science Ventures and BioGeneration Ventures also participated.

Escalier plans to begin clinical trials in mid-2018 of a topical small molecule inhibitor of RAR-related orphan receptor C thymus-specific isoform (RORgamma2; RORgammaT) to treat psoriasis. It is also developing an oral small molecule against the same target.

The company's topical therapy is designed for patients with mild to moderate disease and uses technology intended to curb systemic drug activity and reduce risks of off-target effects. Escalier believes its oral candidate can be an alternative to injectable biologics for patients with moderate to severe psoriasis.

Escalier declined to disclose details about its series A round.

In October, BioGeneration closed its largest fund to date (see BioCentury, Nov. 2).

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

Purchase this article for limited one-time distribution and website posting

$750 USD